论文部分内容阅读
同种骨髓移植(ABMT)已成为治疗慢性髓细胞白血病(CML)的主要方法,治愈率较前提高。1970年以来用高剂量环磷酰胺120mg/kg、全身照射(TBI)做为ABMT的预处理已成为治疗CML的常规方法。1980年以来放射生物学资料表明,分次全身照射(FTBI)优于单次全身照射(STBI),即在等效杀灭白血病细胞的同时对正常组织、特别是肺的损伤较小。作者报道了法国21个移植小组的180例病人的治疗结果。其中126例为STBI组,54例为FIBI组,平均随访40个月。治疗方案中全部病人均用环磷酰胺120mg/kg、FTBI照射量为11.55Gy(10～13.2Gy),STBI
Allogeneic bone marrow transplantation (ABMT) has become the main method for the treatment of chronic myeloid leukemia (CML), and the cure rate is higher than before. Pretreatment with high-dose cyclophosphamide 120 mg/kg and total body irradiation (TBI) as ABMT since 1970 has become a routine method for the treatment of CML. Since 1980, radiobiological data have shown that fractional whole body irradiation (FTBI) is superior to single body irradiation (STBI), which means that equivalent damage to leukemic cells is less damaging to normal tissues, especially the lungs. The author reported the treatment results of 180 patients in 21 transplant groups in France. Of these, 126 were in the STBI group and 54 in the FIBI group with an average follow-up of 40 months. All patients in the treatment plan were treated with cyclophosphamide 120 mg/kg and FTBI exposure was 11.55 Gy (10 to 13.2 Gy). STBI